Influence of glycoprotein IIb/IIIa inhibitors on bleeding events after successful resuscitation and percutaneous coronary intervention

被引：0
|
作者：
Paul Marc Biever
Dawid Leander Staudacher
Jonas Degott
Corinna Nadine Lang
Christoph Bode
Tobias Wengenmayer
机构：
[1] University of Freiburg,Department of Cardiology and Angiology I, Faculty of Medicine, Heart Center Freiburg University
[2] University of Freiburg,Department of Medicine III (Interdisciplinary Medical Intensive Care), Medical Center, Faculty of Medicine
来源：
Clinical Research in Cardiology | 2020年 / 109卷
关键词：
Glycoprotein IIb/IIIa antagonists; Glycoprotein IIb/IIIa inhibitors; Anticoagulation; Bleeding; Cardiac arrest; Resuscitation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：385 / 392
页数：7
相关论文
共 50 条
  • [41] Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes
    Roe, MT
    Sapp, SK
    Lincoff, AM
    CLEVELAND CLINIC JOURNAL OF MEDICINE, 2000, 67 (02) : 131 - 140
  • [42] Safety and benefit of Glycoprotein IIb/IIIa inhibitors in out of hospital cardiac arrest patients treated with percutaneous coronary intervention
    Picard, Fabien
    Sokoloff, Anastasia
    Pham, Vincent
    Diefenbronn, Marine
    Laghlam, Driss
    Seret, Gabriel
    Varenne, Olivier
    Dumas, Florence
    Cariou, Alain
    RESUSCITATION, 2020, 157 : 91 - 98
  • [43] Routine or selective administration of glycoprotein IIb/IIIa receptor inhibitors during elective percutaneous coronary intervention? The ROSA study
    Danzi, GB
    Capuano, C
    Sesana, M
    Baglini, R
    Gandolfo, CM
    Stabile, A
    Savonitto, S
    CIRCULATION, 2003, 108 (17) : 374 - 374
  • [44] Routine or selective administration of glycoprotein IIb/IIIa receptor inhibitors during elective percutaneous coronary intervention? - The ROSA study
    Danzi, GB
    Capuano, C
    Sesana, M
    Baglini, R
    Gandolfo, CM
    Stabile, A
    Savonitto, S
    EUROPEAN HEART JOURNAL, 2003, 24 : 546 - 546
  • [45] Effects of clopidogrel pretreatment before percutaneous coronary intervention in patients treated with glycoprotein IIb/IIIa inhibitors (abciximab or tirofiban)
    Assali, AR
    Salloum, J
    Sdringola, S
    Moustapha, A
    Ghani, M
    Hale, S
    Schroth, G
    Fujise, K
    Anderson, HV
    Smalling, RW
    Rosales, OR
    AMERICAN JOURNAL OF CARDIOLOGY, 2001, 88 (08): : 884 - +
  • [46] Use of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention: insights from the APEX-AMI trial
    Huber, Kurt
    Holmes, David R., Jr.
    van 't Hof, Arnoud W.
    Montalescot, Gilles
    Aylward, Philip E.
    Amadeo Betriu, G.
    Widimsky, Petr
    Westerhout, Cynthia M.
    Granger, Christopher B.
    Armstrong, Paul W.
    EUROPEAN HEART JOURNAL, 2010, 31 (14) : 1708 - 1716
  • [47] A pooled analysis of 3 trials of Bivalirudin versus Heparin and Glycoprotein IIb/IIIa inhibitors during Percutaneous Coronary Intervention
    Kalyanasundaram, Arun
    Sartorius, Jennifer
    Scott, Thomas
    Blankenship, James C.
    AMERICAN JOURNAL OF CARDIOLOGY, 2008, 102 (8A): : 79I - 80I
  • [48] Practicability of Bivalirudin plus Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis
    Li, Senjie
    Lv, Dongqing
    Liu, Caihong
    Jia, Yongping
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2021, 27
  • [49] Bleeding complications of glycoprotein IIb-IIIa receptor inhibitors
    Blankenship, JC
    AMERICAN HEART JOURNAL, 1999, 138 (04) : S287 - S296
  • [50] Evaluation of bleeding complications associated with glycoprotein IIb/IIIa inhibitors
    Brouse, SD
    Wiesehan, VG
    ANNALS OF PHARMACOTHERAPY, 2004, 38 (11) : 1783 - 1788
12345